LMC Endocrinology Centres, Thornhill, Ontario, Canada.
Can J Diabetes. 2011 Dec;35(5):518-27. doi: 10.1016/S1499-2671(11)80008-0.
The leading cause of morbidity and mortality in type 2 diabetes mellitus is cardiovascular disease. There is a need for type 2 diabetes therapies that act in concert with available agents to provide adequate glycemic control without causing hypoglycemia and weight gain, which are associated with increases in cardiovascular risk. Incretin-based agents-dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists-are the newest class of antihyperglycemic therapies. Liraglutide and exenatide, glucagon-like peptide-1 receptor agonists recently approved in Canada, have been shown to effectively lower blood glucose levels while also having beneficial effects on body weight and systolic blood pressure. The objective of this article is to review and discuss incretin-based agents, with a focus on their effects on blood glucose control, body weight and cardiovascular risk factors in patients with type 2 diabetes. Relevant data were obtained by literature search using the EMBASE, MEDLINE and PubMed databases.
2 型糖尿病的主要发病和致死原因是心血管疾病。需要有 2 型糖尿病疗法与现有药物协同作用，在不引起低血糖和体重增加的情况下提供充分的血糖控制，因为低血糖和体重增加与心血管风险增加有关。基于肠促胰岛素的药物——二肽基肽酶-4 抑制剂和胰高血糖素样肽-1 受体激动剂——是最新一类抗高血糖疗法。在加拿大最近批准的利拉鲁肽和艾塞那肽是胰高血糖素样肽-1 受体激动剂，它们已被证明能有效降低血糖水平，同时对体重和收缩压也有有益影响。本文的目的是综述和讨论基于肠促胰岛素的药物，重点是它们对 2 型糖尿病患者的血糖控制、体重和心血管危险因素的影响。相关数据是通过使用 EMBASE、MEDLINE 和 PubMed 数据库进行文献检索获得的。
